These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Cabozantinib: Mechanism of action, efficacy and indications]. Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875 [TBL] [Abstract][Full Text] [Related]
6. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related]
7. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Schlumberger M; Elisei R; Müller S; Schöffski P; Brose M; Shah M; Licitra L; Krajewska J; Kreissl MC; Niederle B; Cohen EEW; Wirth L; Ali H; Clary DO; Yaron Y; Mangeshkar M; Ball D; Nelkin B; Sherman S Ann Oncol; 2017 Nov; 28(11):2813-2819. PubMed ID: 29045520 [TBL] [Abstract][Full Text] [Related]
8. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Dadu R; Hu MN; Grubbs EG; Gagel RF Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
10. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Hoy SM Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653 [TBL] [Abstract][Full Text] [Related]
11. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Viola D; Cappagli V; Elisei R Future Oncol; 2013 Aug; 9(8):1083-92. PubMed ID: 23902240 [TBL] [Abstract][Full Text] [Related]
12. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Grüllich C Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760 [TBL] [Abstract][Full Text] [Related]
13. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373 [TBL] [Abstract][Full Text] [Related]
14. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]
15. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
16. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198 [TBL] [Abstract][Full Text] [Related]
17. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives. Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195 [TBL] [Abstract][Full Text] [Related]
19. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]